Back to Research Home
INCYIncyte Corporation
Health Care · Biotechnology · Large
$115.71−1.04%
As of 23 Oct 2026Mkt cap $26.1B
Stage 13
WAIT
Fundamentals
54.5/75
Technical
7.7/15
Independent
62.1/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- −7.0%
- 3M
- −2.7%
- 6M
- +22.3%
- 1Y
- +31.4%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 14.7xHist median 103.0x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 12.1x
- FCF yield
- 8.3%
Quality
- ROIC
- 60.5%
- Operating margin
- 16.8%
- FCF margin
- 26.3%
- Current ratio
- 3.3x
Growth
- Revenue growth
- +21.2%Latest FY YoY
- Revenue CAGR
- +14.5%
- EPS CAGR
- +10.7%
- FCF CAGR
- +24.2%
Capital
- Share-count trend
- −5.7%3Y annualised
- Net cash
- $3.1B-2.2x OCF
Annual trend
- CAGR 2021–2025
- +14.5%
- Latest · 2025
- $5B
- YoY
- +21.2%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded